Statistics from Altmetric.com
As many active rheumatoid arthritis (RA) patients do not fully respond to biological therapies, there is growing interest in response predictors. Rheumatoid factor (RF) status predicts responses to rituximab; seropositive patients have higher response rates.1,–,5 Smoking status predicts responses to tumour necrosis factor (TNF) inhibitors; non-smokers have higher response rates.6,–,9
We evaluated whether smoking and autoantibody status interact in predicting responses to rituximab in active RA patients treated in routine practice settings. We used National Institute for Health and Clinical Excellence response criteria of falls in Disease Activity Scores for 28 joints (DAS28) of ≥1.2 after 6 months treatment in patients with initial DAS28 scores >5.1.
We studied 150 sequential RA patients receiving rituximab in southeast London and Kent. They comprised 109 women and 41 men, mean age …